Xlfc This performer defines the secret of st0ck selecting

Martin Nutraceuticals Commences Expansion in Global Nutraceutical 
Marketplace.

Watch MTNU on Thursday!


Martin Nutraceuticals Inc. (MTNU)
Approximate Float: 2.5 Million
Currently trading at: 0.91
30 Day Projection: 2.00

Martin Nutraceuticals Commences Expansion in Global Nutraceutical 
Marketplace.

Press Release Source: Martin Nutraceuticals Inc. 

Wednesday February 23, 12:01 pm ET 

RENO, Nev., Feb. 23, 2005 PRIMEZONE. Martin Nutraceuticals Inc. (MTNU) 
is a company focused on developing natural and alternative medicine 
products that provide better health for individuals through the use of 
their wide range of products, which aid in joint therapy, digestive 
therapy, WeightControl, blood circulation and alertness, and overall
improved 
functioning of the b0dy.
 
The flagship product which is based on Joint Therapy is used to aid in 
joint and general arthritic pain. Over 65 million Americans suffer from 
arthritis and osteoporosis. For several years, Dr. A. W. Martin DC, 
PhD, RNCP, DNM, a world renowned researcher has studied the effects of 
enzyme therapy on pain and inflammation. Dr. Martin has developed a unique 
blend of proprietary and patented ``systemic oral enzymes'' designed to 
provide superior anti-inflammatory benefits. Studies have shown that 
Dr. Martin's Joint Therapy, proprietary enzyme formula reduces pain and 
inflammation in 80% of patients who are diagnosed with Osteoarthritis of 
the knees in less than 6-weeks.

In another study conducted the patient Fibromyalgia -- a severe muscle 
pain syndrome that affects more than 20 million North Americans -- 90% 
of patients reported relief from swelling and pain within 4-weeks of 
using Dr. Martin's Joint Therapy formula.

The nutraceuticals market has grown steadily at an incredible rate of 
15-20% annually since 1998. Currently in North America, over 3.9 billion 
is spent on over-the-counter and prescription medication for arthritis, 
joint and muscle related pain alone. Since Dr. Martin's foray into the 
nutraceuticals market, Dr. Martin's products have amassed sales over 35 
million. It is with this track record and knowledge that Martin 
Nutraceuticals has re-branded many of Dr. Martin's successful formulas and
is 
poised to unveil them onto an international platform.

In the weeks and months to come, the company will be unveiling new 
product lines, various sales targets, contracts, distribution agreements 
and clinical data.


About MTNU:

MTNU is becoming quickly recognized in the nutraceutical marketplace 
which will surpass 74.4 billion in the year 2007.  With a growing demand 
for nutraceutical products that provide not only health benefits, but 
also prevent and provide treatment for disease, MTNU provides high 
quality products that use proprietary and patented oral systemic enzymes 
that help in the rapid absorption of the product, resulting in incredibly 
swift, and effective results to symptoms including:

JointPain
Cardiovascular Irregularities 
Digestive Irregularities
Anti-Oxidization
WeightL0ss

MTNU offers individuals a wide array of reliable and effective 
nutraceuticals. Martin Nutraceuticals has created a family of complimentary

medicine and supplementation that has helped thousands of people suffering 
from arthritis and general jointpain, poor circulation, tiredness, 
obesity and digestive complications.  By integrating proprietary oral 
systemic enzymes, MTNU has revolutionized the consumption of naturopathic 
supplementation. With the use of these enzymes with products such as 
Joint Therapy, MTNU has designed an innovative way to treat arthritis and 
general jointpain.

Millions of people in North America suffer from some degree of general 
jointpain.  According to the Arthritis Society, arthritis is North 
America's most common ailment, with over 44 million North Americans 
suffering.  The Wall Street Journal, in the April 19th, 1999 issue states
that 
Aspirin, Ibuprofen (Cox 1) Vioxx, Celebrex (Cox 2) killed 20,000 
Americans a year and put another 100,000 in the hospital suffering with
drug 
side effects including: liver damage, kidney damage and intestinal 
hemorrhaging.  With many of these products being pulled and highly 
regulated because of the potential of deadly side effects, sufferers of 
jointpain are seeking a natural, healthy alternative to aid in their 
suffering. 

MTNU has developed a proprietary therapeutic product, Joint Therapy, 
which is able to benefit all types of arthritis from: Rheumatoid 
Arthritis, sports injuries, pelvic inflammation to cardiac inflammation.
MTNU's 
unique marketing program consists of heavily aired infomercials, direct 
mailorder marketing and large pharmaceutical and retail chains.

Will MTNU explode higher as more and more investors become aware of the 
stock?  If you think so, you may not want to wait until it is too late. 
Remember, timing your trade is critical.

Good Luck and Happy Trading.


Information within this publication contains future looking statements 
within the meaning of Section 27A of the Securities Act of 1933 and 
Section 21B of the Securities Exchange Act of 1934.  Any statements that 
express or involve discussions with respect to predictions, 
expectations, beliefs, plans, projections, objectives, goals, assumptions
or future 
events or performance are not statements of historical fact and may be 
future looking statements. Future looking statements are based on 
expectations, estimates and projections at the time the statements are made

that involve a number of risks and uncertainties which could cause 
actual results or events to differ materially from those presently 
anticipated. Future looking statements in this action may be identified
through 
the use of words such as projects, foresee, expects, will, anticipates, 
estimates, believes, understands or that by statements indicating 
certain actions may, could, or might occur. These future-looking statements

are based on information currently available and are subject to a 
number of risks, uncertainties and other factors that could cause MTNU 's 
actual results, performance, prospects or opportunities to differ 
materially from those expressed in, or implied by, these future-looking 
statements. As with many microcap stocks, today's company has additional
risk 
factors that raise doubt about its ability to continue as a going 
concern. MTNU is not a reporting company registered under the Securities
Act 
of 1934 and hence there is limited public information available about 
the company. These risks, uncertainties and other factors include, 
without limitation, the Company's growth expectations and ongoing funding 
requirements, and specifically, the Company's growth prospects with 
scalable customers. Other risks include the Company's limited operating 
history, the Company's history of operating losses, consumers' acceptance, 
the Company's use of licensed technologies, risk of increased 
competition, the potential need for additional financing, the conditions
and 
terms of any financing that is consummated, the limited trading market for 
the Company's securities, the possible volatility of the Company's 
stock price, the concentration of ownership, and the potential fluctuation 
in the Company's operating results. The publisher of this report does 
not represent that the information contained in this message states all 
material facts or does not omit a material fact necessary to make the 
statements therein not misleading. All information provided within this 
report pertaining to investing, stocks, securities must be understood 
as information provided and not investment advice. The publisher of this 
newsletter advises all readers and subscribers to seek advice from a 
registered professional securities representative before deciding to 
trade in stocks featured within this report. None of the material within 
this report shall be construed as any kind of investment advice or 
solicitation. Many of these companies are on the verge of bankruptcy. You
can 
lose all your money by investing in this stock. The publisher of this 
report is not a registered investment expert. Subscribers should not 
view information herein as legal, tax, accounting or investment advice. 
Any reference to past performance(s) of companies are specially selected 
to be referenced based on the favorable performance of these companies. 
You would need perfect timing to achieve the results in the examples 
given. There can be no assurance of that happening. Remember, as always, 
past performance is not indicative of future results and a thorough due 
diligence effort, including a review of a company's filings at sec gov 
or edgar-online com when available, should be completed prior to 
investing. All factual information in this report was gathered from public 
sources, including but not limited to Company Websites and Company Press 
Releases. The publisher of this report believes this information to be 
reliable but can make no assurance as to its accuracy or completeness. 
Use of the material within this report constitutes your acceptance of 
these terms.  In compliance with the Securities Act of 1933, Section17 
b, The publisher of this newsletter discloses the receipt of ten 
thousand dollars from a third party, not an officer, director or affiliate 
shareholder for the circulation of this report.  Be aware of an inherent 
conflict of interest resulting from such compensation due to the fact 
that this is a paid advertisement and is not without bias.The party that 
paid us has a position in the stock they will sell at anytime without 
notice. This could have a negative impact on the price of the stock.




to the world. But Washington is on display at least once every four years
and is an accommodating
Californians celebrated with a Hollywood flair, and this year, once again,
Texans will party

Washington may be one of the country's Democraticstrongholds, the bluest of
blue metropolitan areas, but this week it is more than receptive
tuqfmjnaay.dcy6ymjvoobliu.cs9jlguhqdo.ncorkmknb

_______________________________________________
gal-hackers maillist  -  [email protected]
http://lists.ximian.com/mailman/listinfo/gal-hackers